A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
Crossref DOI link: https://doi.org/10.1186/s12885-016-2124-5
Published Online: 2016-02-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tarpgaard, Line S.
Qvortrup, Camilla
Nygård, Sune B.
Nielsen, Signe L.
Andersen, Diana R.
Jensen, Niels Frank
Stenvang, Jan
Detlefsen, Sönke
Brünner, Nils
Pfeiffer, Per
Funding for this research was provided by:
The Danish Cancer Society (grant number R72-A4686-I3-S2)
